Developer docs
API playgroundTry for free, no card

Search company profiles

Micro Imaging Technology

Full company profile

uuid00235ux

Namestring
Micro Imaging Technology
Legal namestring
Micro Imaging Technology, Inc.
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Micro Imaging Technology, Inc. (MIT) is a California-based public company trading under the ticker MMTC that develops laser-based rapid microbial identification technology for laboratory use. Its flagship product, the MIT 1000, is an AOAC-certified system that uses 35 photo detectors arranged around a sample vial to collect light scattering intensities generated when bacterial cells intersect a laser beam, enabling identification of pathogenic bacteria within minutes of culturing. The system is sold to food safety testing laboratories as the primary customer segment, with environmental monitoring facilities as a secondary use case, replacing slower traditional culturing and identification methods.

Short descriptiontext

California-based public company Micro Imaging Technology (MMTC) develops the MIT 1000, an AOAC-certified laser-based rapid microbial identification system for food safety and environmental labs. It is expanding into medical aesthetics and regenerative medicine through acquisitions of SaltMed/SaltFacial and Cellmyx.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Clemente, United States
HQ citystring
San Clemente
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbial identification, pathogen detection, food safety testing, laser-based detection, laboratory instrumentation
Industry2 codes
1Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
CodeHLAAALACPrimaryYes
2Microscopy, Imaging & Flow Cytometry Instruments
CodeHLAGAIAEPrimaryNo
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Surgical and Medical Instrument Manufacturing339112
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Surgical & Medical Instruments & Apparatus3841
Product category
Laboratory Instrumentation
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Laboratory Equipment Sales
TypeHardware Sales
Description

Sale of MIT 1000 microbial identification instruments to laboratories and industrial facilities for pathogen detection and food safety testing.

micro-id.co
2Consumables and Reagents
TypeUsage Based
Description

Ongoing consumables sales for the MIT 1000 system operation, including sample vials and identification reagents.

micro-id.co
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1MIT 1000
Description

AOAC-certified, laser-based rapid microbial identification system capable of identifying pathogenic bacteria in minutes.

micro-id.co
Core offering1 text field

Micro Imaging Technology develops and sells the MIT 1000, an AOAC-certified, laser-based rapid microbial identification system that uses light scattering technology with 35 photo detectors to identify pathogenic bacteria within minutes after culturing. The company sells this laboratory instrument to food safety testing laboratories and environmental monitoring facilities, and has expanded its portfolio through acquisitions of SaltMed/SaltFacial (aesthetic products) and Cellmyx (regenerative medicine, FDA-cleared intelliFat BOD device).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Micro Imaging Technology offers a portfolio combining proprietary microbial identification technology with acquired aesthetics and regenerative medicine products. The core offering is the MIT 1000, an AOAC-certified laser-based rapid microbial identification system for pathogenic bacteria detection. The company has expanded through strategic acquisitions: SaltMed/SaltFacial (December 2025) and Cellmyx (June 2026), which brings the FDA-cleared intelliFat® BOD™ device for orthopedic and cosmetic surgery applications. The combined portfolio is designed to enable expanded manufacturing and distribution nationally and worldwide.

Product and service3 records
1MIT 1000 Rapid Microbial Identification System
2intelliFat BOD
3SaltMed/SaltFacial
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-05
Description

Micro Imaging Technology acquired Cellmyx, a 25-year-old FDA-registered manufacturer specializing in autologous adipose grafting and regenerative medicine. Cellmyx holds FDA 510(k) clearance for the intelliFat BOD device used in orthopedic and cosmetic surgery. This acquisition complements MIT's earlier purchase of SaltMed/SaltFacial, creating a combined portfolio that strengthens MIT's manufacturing and distribution capabilities nationally and worldwide.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

MIT acquired SaltMed/SaltFacial in December 2025, establishing a foundation in the aesthetics and regenerative medicine space prior to the Cellmyx acquisition.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Offers the iQ-Check PCR-based pathogen detection systems and other microbiology workflows for the food-safety testing market. Comparable customer segment to MIT 1000 with similar goal of rapid, certified pathogen identification.

TypeDirect peer
Description

Maker of the MALDI Biotyper, the dominant rapid microbial identification platform in clinical and food-safety labs. Directly competes with the MIT 1000 on speed and accuracy for pathogen ID, but uses mass spectrometry rather than light scattering.

TypeBroad incumbent
Description

Global leader in microbiology diagnostics (VITEK, BioBall) serving clinical and industrial food-safety labs. Highly comparable to MIT 1000's microbial identification mission but at vastly larger scale with broader organism libraries and installed base.

TypeBroad incumbent
Description

Major supplier of microbiology diagnostics and lab automation (BD Phoenix, BD MAX) to clinical and industrial labs. Overlaps with MIT 1000 in food-safety and environmental testing customer base.

TypeBroad incumbent
Description

Diversified life-sciences instrument vendor (MicroSEQ, Applied Biosystems) with food-safety and clinical microbiology offerings. Overlaps with MIT 1000 on microbial ID workflows, especially in industrial and food-testing labs.

TypeOthers
Description

Supplies microbiology consumables, media, and identification reagents used by food-safety and clinical labs. Comparable as a consumables/reagents ecosystem participant adjacent to MIT 1000's recurring-revenue business.

TypeEmerging player
Description

Developer of rapid phenotypic antimicrobial susceptibility testing (AST) and identification platforms for clinical microbiology. Comparable to MIT 1000's value proposition of minutes-to-hours vs days for traditional methods, though focused on clinical ID/AST.

TypeEmerging player
Description

Developed T2 Magnetic Resonance-based rapid diagnostics for bloodstream and other infections. Comparable emerging-player profile and 'minutes-to-hours' value proposition to MIT 1000, though focused on clinical sepsis.

TypeDirect peer
Description

Provides end-to-end microbial identification, QC, and lab services to food, cosmetic, and pharmaceutical manufacturers. Comparable to MIT's target customer base for outsourced and in-house food-safety microbial workflows.

TypeDirect peer
Description

Industrial division of bioMérieux offering rapid microbial testing for food and beverage producers. Direct overlap with the MIT 1000's food-safety value proposition of faster, AOAC-equivalent identification.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Micro Imaging Technology

Laboratory Instrumentationmicro-identification.com

California-based public company Micro Imaging Technology (MMTC) develops the MIT 1000, an AOAC-certified laser-based rapid microbial identification system for food safety and environmental labs. It is expanding into medical aesthetics and regenerative medicine through acquisitions of SaltMed/SaltFacial and Cellmyx.

What Micro Imaging Technology does

Micro Imaging Technology, Inc. (MIT) is a California-based public company trading under the ticker MMTC that develops laser-based rapid microbial identification technology for laboratory use. Its flagship product, the MIT 1000, is an AOAC-certified system that uses 35 photo detectors arranged around a sample vial to collect light scattering intensities generated when bacterial cells intersect a laser beam, enabling identification of pathogenic bacteria within minutes of culturing. The system is sold to food safety testing laboratories as the primary customer segment, with environmental monitoring facilities as a secondary use case, replacing slower traditional culturing and identification methods.

Micro Imaging Technology firmographics

Firmographics
Name
Micro Imaging Technology
Legal name
Micro Imaging Technology, Inc.
Website
https://micro-identification.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
1–10 employees
Short description
California-based public company Micro Imaging Technology (MMTC) develops the MIT 1000, an AOAC-certified laser-based rapid microbial identification system for food safety and environmental labs. It is expanding into medical aesthetics and regenerative medicine through acquisitions of SaltMed/SaltFacial and Cellmyx.
Ownership category
akta.pro rank

Micro Imaging Technology industry classification

Industry
Product category
Laboratory Instrumentation
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)
akta.pro secondary industry
Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

Keywords

  • Microbial identification
  • Pathogen detection
  • Food safety testing
  • Laser-based detection
  • Laboratory instrumentation

Where Micro Imaging Technology is headquartered

Location

Headquarters

HQ city
San Clemente
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Micro Imaging Technology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Laboratory Equipment Sales: Sale of MIT 1000 microbial identification instruments to laboratories and industrial facilities for pathogen detection and food safety testing.
  2. Consumables and Reagents: Ongoing consumables sales for the MIT 1000 system operation, including sample vials and identification reagents.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Micro Imaging Technology product offering

Product offering

Core offering

Micro Imaging Technology develops and sells the MIT 1000, an AOAC-certified, laser-based rapid microbial identification system that uses light scattering technology with 35 photo detectors to identify pathogenic bacteria within minutes after culturing. The company sells this laboratory instrument to food safety testing laboratories and environmental monitoring facilities, and has expanded its portfolio through acquisitions of SaltMed/SaltFacial (aesthetic products) and Cellmyx (regenerative medicine, FDA-cleared intelliFat BOD device).

Product overview

Micro Imaging Technology offers a portfolio combining proprietary microbial identification technology with acquired aesthetics and regenerative medicine products. The core offering is the MIT 1000, an AOAC-certified laser-based rapid microbial identification system for pathogenic bacteria detection. The company has expanded through strategic acquisitions: SaltMed/SaltFacial (December 2025) and Cellmyx (June 2026), which brings the FDA-cleared intelliFat® BOD™ device for orthopedic and cosmetic surgery applications. The combined portfolio is designed to enable expanded manufacturing and distribution nationally and worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • MIT 1000: AOAC-certified, laser-based rapid microbial identification system capable of identifying pathogenic bacteria in minutes.

Products and services

  • MIT 1000 Rapid Microbial Identification System
  • intelliFat BOD
  • SaltMed/SaltFacial

Companies that use Micro Imaging Technology

Customer profile

Segments2 records

Ideal customer profiles2 records

Micro Imaging Technology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Micro Imaging Technology partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • CellmyxcoreStrategic or Co-development Partner · 5 June 2026Micro Imaging Technology acquired Cellmyx, a 25-year-old FDA-registered manufacturer specializing in autologous adipose grafting and regenerative medicine. Cellmyx holds FDA 510(k) clearance for the intelliFat BOD device used in orthopedic and cosmetic surgery. This acquisition complements MIT's earlier purchase of SaltMed/SaltFacial, creating a combined portfolio that strengthens MIT's manufacturing and distribution capabilities nationally and worldwide.
  • SaltMed/SaltFacialcoreStrategic or Co-development Partner · 1 December 2025MIT acquired SaltMed/SaltFacial in December 2025, establishing a foundation in the aesthetics and regenerative medicine space prior to the Cellmyx acquisition.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Micro Imaging Technology competitors and assessment

Company assessment

Direct peers

  • Bio-Rad Laboratories: Offers the iQ-Check PCR-based pathogen detection systems and other microbiology workflows for the food-safety testing market. Comparable customer segment to MIT 1000 with similar goal of rapid, certified pathogen identification.
  • Bruker Corporation: Maker of the MALDI Biotyper, the dominant rapid microbial identification platform in clinical and food-safety labs. Directly competes with the MIT 1000 on speed and accuracy for pathogen ID, but uses mass spectrometry rather than light scattering.
  • Charles River Laboratories: Provides end-to-end microbial identification, QC, and lab services to food, cosmetic, and pharmaceutical manufacturers. Comparable to MIT's target customer base for outsourced and in-house food-safety microbial workflows.
  • bioMérieux (Industrial Microbiology): Industrial division of bioMérieux offering rapid microbial testing for food and beverage producers. Direct overlap with the MIT 1000's food-safety value proposition of faster, AOAC-equivalent identification.

Broad incumbents

  • bioMérieux: Global leader in microbiology diagnostics (VITEK, BioBall) serving clinical and industrial food-safety labs. Highly comparable to MIT 1000's microbial identification mission but at vastly larger scale with broader organism libraries and installed base.
  • Becton, Dickinson and Company (BD): Major supplier of microbiology diagnostics and lab automation (BD Phoenix, BD MAX) to clinical and industrial labs. Overlaps with MIT 1000 in food-safety and environmental testing customer base.
  • Thermo Fisher Scientific: Diversified life-sciences instrument vendor (MicroSEQ, Applied Biosystems) with food-safety and clinical microbiology offerings. Overlaps with MIT 1000 on microbial ID workflows, especially in industrial and food-testing labs.

Others

Emerging players

  • Accelerate Diagnostics: Developer of rapid phenotypic antimicrobial susceptibility testing (AST) and identification platforms for clinical microbiology. Comparable to MIT 1000's value proposition of minutes-to-hours vs days for traditional methods, though focused on clinical ID/AST.
  • T2 Biosystems: Developed T2 Magnetic Resonance-based rapid diagnostics for bloodstream and other infections. Comparable emerging-player profile and 'minutes-to-hours' value proposition to MIT 1000, though focused on clinical sepsis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Micro Imaging Technology social profiles

Digital presence

Micro Imaging Technology compliance and trust

Trust signal

Compliance1 record

Micro Imaging Technology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Micro Imaging Technology leadership team

Management profile

Number of profiles

Micro Imaging Technology subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Micro Imaging Technology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Micro Imaging Technology M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Micro Imaging Technology

What does Micro Imaging Technology do?

Micro Imaging Technology develops and sells the MIT 1000, an AOAC-certified, laser-based rapid microbial identification system that uses light scattering technology with 35 photo detectors to identify pathogenic bacteria within minutes after culturing. The company sells this laboratory instrument to food safety testing laboratories and environmental monitoring facilities, and has expanded its portfolio through acquisitions of SaltMed/SaltFacial (aesthetic products) and Cellmyx (regenerative medicine, FDA-cleared intelliFat BOD device).

Is Micro Imaging Technology a public or private company?

Micro Imaging Technology is a public company. It is classified as public and is currently operating.

When was Micro Imaging Technology founded?

Micro Imaging Technology was founded in 2005. It employs 1 to 10 people.

Where is Micro Imaging Technology based?

Micro Imaging Technology is headquartered in San Clemente, United States, in the North America region.

How does Micro Imaging Technology make money?

Two revenue lines are on record. Laboratory Equipment Sales are the primary driver. The others are consumables and Reagents.

Who are Micro Imaging Technology's main competitors?

Direct peers on record are Bio-Rad Laboratories, Bruker Corporation, Charles River Laboratories and bioMérieux (Industrial Microbiology). Broad incumbents are bioMérieux, Becton, Dickinson and Company (BD) and Thermo Fisher Scientific. MilliporeSigma (Sigma-Aldrich / Merck KGaA Life Science) is listed as an others. Emerging players are Accelerate Diagnostics and T2 Biosystems.

Does Micro Imaging Technology have an API?

No public API is recorded for Micro Imaging Technology.

What industry is Micro Imaging Technology in?

Micro Imaging Technology's product category is Laboratory Instrumentation. Its primary akta.pro industry code is HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels), with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournMicro Imaging Technology is pleased to Announce the Acquisition of CellmyxMicro Imaging Technology, Inc. (MIT), a California-based public company trading as MMTC, announced the acquisition of Cellmyx, a 25-year-old FDA-registered manufacturer specializing in autologous adipose grafting and regenerative medicine, including the FDA-cleared intelliFat® BOD™ device for orthopedic and cosmetic surgery applications. This acquisition complements MIT's December 2025 purchase of SaltMed/SaltFacial, creating a combined portfolio that strengthens MIT's ability to expand manufacturing and distribution nationally and worldwide. MIT intends to continue exploring additional opportunities in the aesthetics and regenerative medicine space.PR NewswireMicro Imaging Technology is pleased to Announce the Acquisition of CellmyxMicro Imaging Technology, Inc. (MIT), a California-based public company, announced the acquisition of Cellmyx, a manufacturer specializing in autologous adipose grafting and regenerative medicine products for cosmetic and orthopedic surgery. Cellmyx holds FDA 510(k) clearance for its intelliFat® BOD™ device and has operated for 25 years under the name Millennium Medical Technologies Inc., positioning it as a leader in adipose tissue transfer technology. The acquisition complements MIT's earlier purchase of SaltMed/SaltFacial in December 2025, with the combined companies aiming to expand manufacturing and distribution nationally and worldwide.GlobeNewswireMicro Imaging Technology's Eye on the FutureMicro Imaging Technology announced progress on its MIT 1000 microbial identification system, including a 65% reduction in liabilities and first commercial units in November 2012. The company expects AOAC certification for E. coli and Salmonella this year, with 2013 planned as a growth year.GlobeNewswireStockTradersTalk Interviews Micro Imaging Technology, Inc. Chairman and CEO, Michael BrennanMichael Brennan, CEO and Chairman of Micro Imaging Technology, was interviewed on November 17, 2011, discussing the company's patented bacteria identification system. The system identifies pathogens in under five minutes, with food safety testing expected to surpass $4.7 billion by 2015. The interview also covered business outlook and recent achievements.GlobeNewswireMicro Imaging Technology Expands the EPIC Alliance -- Receives Initial Purchase OrderMicro Imaging Technology announced a long-term equity alliance with EPIC Corporation, including a stock purchase agreement and EPIC's initial order of five MIT 1000 systems. The order is valued at roughly $200,000, with EPIC planning to sell over 30 systems within a year, generating over $1 million in initial revenue.GlobeNewswireEPIC and Micro Imaging Technology Enter Strategic Alliance and EPIC Declares Stock DividendEPIC Corporation announced an equity investment in Micro Imaging Technology, a master distribution agreement for MIT's products, and a 1:1 stock dividend. The company expects to sell about 30 licenses within a year, generating roughly $900,000 in one-time fees. EPIC Healthcare, LLC will serve as the master distributor.GlobeNewswireMicro Imaging Technology, Inc. Concludes the Divine Capital Markets, LLC LitigationMicro Imaging Technology settled a lawsuit with Divine Capital Markets over convertible debentures, with neither side admitting liability. Debenture holders received 5,899,997 unrestricted common shares and released patent claims. The company will focus on growth.GlobeNewswireMicro Imaging Technology, Inc. Provides an Update on Litigation Against Divine Capital Markets, LLCDivine Capital Markets and investors sued Micro Imaging Technology, alleging breach of contract and fraud over secured convertible debentures. A temporary restraining order was vacated on May 19, and the company intends to defend the lawsuit.GlobeNewswireTaglich Brothers Initiates Coverage of Micro Imaging Technology, Inc.Taglich Brothers initiated coverage of Micro Imaging Technology, Inc., a development-stage company focused on microbial detection systems. The company paid a $6,000 engagement fee in June 2008 and will pay a $2,000 monthly fee for research reports.GlobeNewswireMicro Imaging Technology, Inc. Retains Taglich Brothers, Inc. for Research and Analytical CoverageMicro Imaging Technology, Inc. retained Taglich Brothers, Inc. for research and analytical coverage. The company's patented system identifies up to 23 bacterial species in minutes at a penny per test, with 95% accuracy on over 300 tests. The firm aims to provide broader investor information as it grows.